News & Events

News

All categories

Earnings

Press Release

All years

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood

November 19, 2020

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

November 10, 2020

Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets

November 9, 2020

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells

November 9, 2020

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

November 5, 2020

Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition

November 4, 2020

Affimed to Present at Upcoming Investor Conferences

November 4, 2020

Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020

November 3, 2020

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

October 20, 2020

Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 14, 2020

Events

All

Scientific

Investors

05Dec

62nd ASH Annual Meeting and Exposition

December 5 - 8, 2020 (digital)

11Jan

J.P.Morgan

January 11 - 14, 2021 (digital)

Webcasts
More events